Navigation Links
Genzyme Provides Update on Myozyme(R) Manufacturing

Will Host Conference Call Today at 5:00 p.m.

CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA has informed the company of its opinion that Myozyme(R) (alglucosidase alfa) produced at the 160L bioreactor scale and Myozyme produced at the 2000L scale should be classified as two different products because of differences in the carbohydrate structures of the molecules. Currently, Genzyme has U.S. approval to sell Myozyme manufactured at the 160L scale, and the company has been seeking clearance from the FDA for Myozyme produced at the 2000L scale. Production at this larger scale has already been approved in more than 40 countries.

Based on the global clinical experience of nearly 900 patients of all ages currently receiving Myozyme produced at the larger scale, including patients who participated in the Late-Onset Treatment Study (LOTS), Genzyme believes that Myozyme produced at both the 160L and 2000L scales is clinically effective and safe. Myozyme is the only treatment for Pompe disease -- a severe, progressively debilitating and life-threatening inherited disorder affecting a very small number of people throughout the world.

The FDA will require Genzyme to submit a separate biologics license application (BLA) to gain approval for Myozyme produced at the 2000L scale. The agency proposed that Genzyme initiate a rolling BLA review process by submitting results from the LOTS study. Genzyme expects the FDA to give the BLA priority review and to act on the application by the end of this year. The LOTS study, which met its co-primary efficacy endpoints, was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients with Pompe disease. Genzyme had already been preparing to submit results from this study to the FDA to fulfill a post-marketing commitment. Genzyme anticipates that this process will culminate in the availability of two commercial versions of Myozyme in the United States: one produced at the 160L scale and the other produced at the 2000L scale. The company expects to begin providing U.S. patients with commercial 2000L Myozyme during the first quarter of 2009.

To ensure that severely affected adults with Pompe disease in the United States have access to treatment, Genzyme, in collaboration with the FDA, created the Myozyme Temporary Access Program (MTAP) in May 2007. Through this program the company is currently providing Myozyme produced at the 2000L scale free of charge to approximately 140 patients. Infants and children with Pompe disease in the United States continue to receive commercially approved Myozyme produced at the 160L scale.

"We are extremely disappointed in the FDA's decision because it will further delay broad patient access to Myozyme, which is not possible under the MTAP program," said Henri A. Termeer, Genzyme's chairman and chief executive officer.

Financial Impact

Myozyme sales for 2008 are now expected to be approximately $275-$285 million compared to previous guidance of $320-$330 million, reflecting the delay in the approval of 2000L production. Genzyme anticipates that this delay will have an impact on 2008 non-GAAP earnings of approximately $0.10 per diluted share. This reflects both forgone commercial sales margin and the costs of continued administration of the MTAP program. Genzyme now expects 2008 non-GAAP earnings of approximately $3.90 per diluted share, compared with previous guidance of $4.00 per diluted share. GAAP earnings for 2008 are now expected to be approximately $2.65 per diluted share, compared with previous guidance of $2.75 per diluted share. GAAP figures include anticipated amortization and stock-compensation expenses and the effect of contingent convertible debt. Genzyme reaffirmed its commitment to 20 percent compound average growth in non-GAAP earnings per share through 2011.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its 2008 earnings guidance; its 2008 Myozyme revenue guidance; its plans regarding the timing and content of the BLA submission for Myozyme manufactured at the 2000L scale; it expectations regarding FDA approval of that BLA and the timing thereof; its anticipated non-GAAP compound growth rate through 2011; and its belief there is no difference in the clinical effectiveness or safety of Myozyme produced at the 160L and the 2000L scales. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain and maintain regulatory approvals for Myozyme produced at the 2000L scale and the timing thereof; Genzyme's ability to accurately anticipate regulatory actions on its Myozyme manufacturing applications; Genzyme's ability to manufacture its products, including Myozyme, in a timely and cost effective manner and in sufficient quantities to meet demand; Genzyme's ability to accurately forecast Myozyme revenues and the impact of reduced Myozyme revenues and other costs associated with the regulatory delay on earnings; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Myozyme(R) are registered trademarks Genzyme Corp. All rights reserved.

Conference Call Information

Genzyme will host a conference call today at 5:00 p.m. Eastern to discuss Myozyme manufacturing. To participate in the call, please dial 1-773-799-3828 and use passcode "Genzyme." The replay number for the call is 203-369-3292, and the replay will be available until midnight on May 5th. Today's call will also be Webcast on the investor events section of

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact:

Bo Piela

(617) 768-6579

Investor Contact:

Patrick Flanigan

(617) 768-6563

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
2. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
3. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
4. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
7. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
8. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
9. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
10. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
11. Genzyme Launches Cholestagel(R) in Europe
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):